Tasmanian man dies after COVID-19 ワクチン
A 44-year-old Tasmanian man has died from a rare 血 clotting disorder after receiving his first dose of the AstraZeneca coronavirus ワクチン.
明言する／公表する public health 公式の／役人s said the man, who died last 週末, was a 確認するd 事例／患者 of thrombocytopenia syndrome (TTS).
"On に代わって of the Tasmanian 政府, and 本人自身で, I 延長する my deepest sympathies to the man's family, friends and loved ones," Health 大臣 Jeremy Rockliff said on Thursday.
The man was vaccinated in a Tasmanian 明言する／公表する ワクチン接種 clinic.
Tasmanian 明言する／公表する Health 指揮官 Kathrine Morgan-Wicks said TTS was a rare but serious 条件 that 影響する／感情s two in 100,000 Australians who receive a first dose of the AstraZecena ワクチン.
Five deaths from TTS have been 報告（する）／憶測d に引き続いて the 治めるing of 6.1 million AstraZeneca doses. All are linked to people receiving their first dose.
The 原因（となる） of the man's death will be 調査／捜査するd by the 検死官.
"People in this gentleman's age group had been advised to 重さを計る up the 危険s 利益s (of AstraZeneca) carefully for several months certainly before this ワクチン was 供給するd," 明言する／公表する Public Health Director 示す Veitch said.
"All ワクチンs carry 危険s. We're 存在 very frank with people telling them that in this instance someone has had the AstraZeneca ワクチン and has developed a serious 複雑化.
"The public does need to know that there are 味方する 影響s but they also need to know there are 利益s from ワクチンs."
The 治療力のある Goods 行政 was also 通知するd of a 48-year-old Victorian woman's death linked to AstraZeneca and TTS in the past week.
Pfizer remains the recommended ワクチン for Australians under 60 予定 to the 極端に rare 血 clotting 条件 linked to AstraZeneca.
Ms Morgan-Wicks said people should 捜し出す 即座の 医療の attention if they develop symptoms like 厳しい or 執拗な 頭痛s, blurred 見通し, 混乱 or seizures, shortness of breath, chest 苦痛, 脚 swelling or 執拗な 復部の 苦痛.
Mr Rockliff said it was normal for people to feel a degree of 不確定 after 審理，公聴会 the news but 公式文書，認めるd "ワクチン接種 is the best way of guarding against COVID-19".
